Bausch + Lomb's Dry Eye Disease Prescription Momentum Builds, Forex Turns as Modest Headwind in Q3, RBC Says
MT newswire2026/10/08 14:5110:51 AM EDT, 10/08/2026 (MT Newswires) -- Bausch + Lomb's (BLCO) Miebo trends indicate it became the largest branded prescription drug for dry eye disease in Q3, but foreign exchange will likely become a modest headwind during the quarter, RBC Capital Markets said in a Thursday research report. The company is due to report Q3 results on Oct. 28. Xiidra's total prescription declines are moderating, with the improvement in gross-to-net pricing offsetting the volume drag, analysts wrote. The brokerage said it expects Q3 revenue of $1.38 billion and adjusted earnings before interest, taxes, depreciation, and amortization of $275 million. For the contact lens and consumer segment, it estimates revenue of $285 million and $483 million, respectively. The firm said focus remains on near-term launches, potential product recalls and impact on 2026 guidance following the Food and Drug Administration's September warning letter to the company's Tampa manufacturing facility, citing Current Good Manufacturing Practice violations in aseptic processing. The brokerage said it reiterated its outperform rating on the stock and price target of $21 per share. Price: 17.15, Change: -0.19, Percent Change: -1.08
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
